In this prospective study of using 5-azacitidine (AZA) as a “bridge to transplant” in 25 adults with myelodysplastic syndrome (MDS), researchers concluded that pre-transplant AZA “was well tolerated and provided reasonable disease control before allogeneic HCT.” AZA was administered a median of 3 cycles (range 0-6) until a suitable transplant donor was found. Pre-transplant responses to AZA were 48% partial response, 33% stable disease, and 19% progressive disease. In the 21 patients who proceeded to transplant, one-year relapse-free and overall survival were 52% and 62%, respectively.
Nishihori T, et al. Biol Blood Marrow TransplantChoose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Pre-Transplant 5-AZA Provides Disease Control in High-Risk MDS
Mar 2014